Litcius/Paper detail

Synthesis of new 3‐(hydroxymethyl)‐2‐phenyl‐2,3 dihydroquinolinone and <i>in‐silico</i> evaluation of <scp>COVID</scp>‐19 main protease inhibitor

Nepolraj Amaladoss, V. I. Shupeniuk, Manisekar Sathiyaseelan, Nagamuthu Prakash

2021Vietnam Journal of Chemistry10 citationsDOIOpen Access PDF

Abstract

Abstract An exclusive approach towards the synthesis of novel 3‐(hydroxymethyl)‐2‐phenyl‐2,3 dihydroquinolin‐4(1 H )‐one and it's in‐silico evaluation as inhibitor of COVID‐19 main protease. The one‐pot synthesis of an established procedure Claisen ester condensation reaction was sodium hydride mediated with intramolecular cyclization with solvent free conditions. The structures of the synthesized compound were confirmed by IR, 1H,13C NMR, and EI‐MS spectral studies. Chemo‐informatics study showed that the compound obeyed the Lipinski's rule, PASS, Swiss ADME. Computational docking analysis was performed using PyRx, AutoDock Vina option based on scoring functions. In‐silico molecular docking study results demonstrated Greater binding energy and affinity to the active pocket the N3 binding site of the Coronavirus primary protease.

Topics & Concepts

HydroxymethylIn silicoCoronavirus disease 2019 (COVID-19)ChemistryStereochemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCombinatorial chemistryVirologyBiochemistryMedicineOutbreakInfectious disease (medical specialty)DiseasePathologyGeneSynthesis and biological activityChemical synthesis and alkaloidsComputational Drug Discovery Methods
Synthesis of new 3‐(hydroxymethyl)‐2‐phenyl‐2,3 dihydroquinolinone and <i>in‐silico</i> evaluation of <scp>COVID</scp>‐19 main protease inhibitor | Litcius